respiratori
viral
infect
rvi
common
caus
ill
human
infect
tend
mild
selflimit
healthi
individu
sever
even
lifethreaten
diseas
seen
immunocompromis
host
well
young
elderli
particular
rvi
frequent
associ
signific
morbid
follow
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
sot
number
rna
dna
virus
caus
respiratori
tract
infect
chapter
focus
epidemiolog
clinic
manifest
diagnosi
treatment
prevent
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
human
metapneumoviru
hmpv
influenza
virus
human
coronavirus
hcov
human
rhinovirus
hrv
respiratori
virus
associ
wide
rang
clinic
syndrom
gener
popul
includ
common
cold
pharyng
tracheobronch
laryngotracheobronch
croup
bronchiol
pneumonia
transplant
recipi
diseas
spectrum
similarli
span
asymptomat
mild
infect
lifethreaten
lower
respiratori
tract
involv
although
sever
complic
tend
frequent
sever
outcom
infect
larg
depend
type
viru
well
host
factor
includ
type
transplant
degre
immunosuppress
time
infect
coinfect
pulmonari
pathogen
includ
bacteria
fungi
eg
aspergillu
speci
pneumocysti
jiroveci
virus
like
cmv
one
respiratori
virus
also
common
complic
treatment
lead
poorer
outcom
hsct
recipi
rvi
occur
patient
first
day
posttransplant
cumul
incid
vari
percent
eg
hmpv
influenza
rsv
piv
hcov
hrv
infect
rsv
influenza
hmpv
piv
adenoviru
higher
risk
progress
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
tend
caus
seriou
diseas
mortal
rate
among
lrti
hrv
hcov
infect
tend
mild
sever
lrti
virus
rare
occur
risk
factor
diseas
progress
lrti
includ
preengraft
statu
allogen
transplant
myeloabl
condit
graftversu
host
diseas
lymphopenia
sot
recipi
also
suffer
sever
diseas
complic
rvi
risk
factor
diseas
progress
well
defin
lung
heartlung
transplant
particularli
vulner
cumul
rate
rvi
lung
transplant
recipi
rang
retrospect
studi
year
high
incid
progress
lrti
report
contrast
incid
rvi
among
heart
liver
kidney
transplant
recipi
similar
gener
popul
although
complic
frequent
addit
direct
effect
viral
infect
rvi
may
promot
immunolog
mediat
lung
injuri
hsct
lung
transplant
recipi
potenti
lead
acut
allograft
reject
case
lung
transplant
recipi
andor
develop
bronchiol
obliteran
syndrom
bo
character
progress
circumferenti
fibrosi
small
termin
airway
histopatholog
result
fix
airflow
obstruct
bo
major
limit
factor
longterm
surviv
lung
transplant
report
incid
bo
associ
rvi
rang
incid
acut
reject
associ
rvi
vari
high
hsct
bo
often
observ
set
chronic
graftversushost
diseas
also
associ
rvi
among
respiratori
virus
rsv
piv
hmpv
influenza
associ
bo
mortal
associ
virus
lung
transplant
patient
heart
liver
kidney
transplant
relationship
rvi
reject
note
rsv
two
subtyp
b
former
typic
caus
sever
diseas
subtyp
simultan
circul
outbreak
distinct
genotyp
subtyp
predomin
within
commun
domin
strain
also
shift
yearli
shift
viral
strain
along
wane
protect
immun
natur
infect
might
account
frequent
reinfect
throughout
life
rsv
usual
caus
mild
selflimit
urti
healthi
older
children
nonelderli
adult
certain
patient
popul
risk
develop
sever
rsv
infect
includ
prematur
young
infant
elderli
patient
comorbid
immunocompromis
host
rsv
associ
apnea
young
preterm
infant
caus
sever
lrti
children
includ
bronchiol
pneumonia
acut
respiratori
failur
among
adult
infect
rsv
symptomat
lower
respiratori
tract
sign
symptom
occur
quarter
patient
sign
urti
includ
cough
rhinorrhea
conjunct
compar
influenza
rsv
frequent
associ
nasal
congest
ear
sinu
involv
product
cough
longer
durat
ill
transplant
patient
rsv
lead
caus
viral
respiratori
tract
infect
among
hsct
recipi
incid
may
high
winter
month
urti
preced
pneumonia
patient
approxim
patient
urti
progress
pneumonia
median
day
attribut
mortal
among
hsct
patient
rang
recent
studi
show
mortal
rate
risk
factor
develop
lrti
includ
allogen
transplant
mismatch
unrel
transplant
presenc
graft
versu
host
diseas
myeloabl
regimen
advanc
age
prolong
lymphopenia
relaps
malign
lack
engraft
sot
recipi
rsvassoci
mortal
rate
significantli
lower
experienc
hsct
although
mortal
rate
among
lung
transplant
patient
report
report
favor
outcom
lung
transplant
recipi
even
absenc
specif
antivir
treatment
studi
suggest
rsvinfect
patient
develop
longterm
pulmonari
dysfunct
worsen
bo
stage
treatment
modal
rsv
limit
ribavirin
without
addit
immunomodulatori
agent
andor
corticosteroid
current
food
drug
administr
fda
approv
therapi
rsv
aerosol
ribavirin
licens
treatment
rsv
lrti
hospit
highrisk
infant
young
children
ribavirin
synthet
nucleosid
analog
broad
spectrum
activ
mani
rna
dna
virus
vitro
vivo
competit
inhibit
inosin
monophosph
dehydrogenas
incorpor
viral
genom
lead
lethal
mutagenesi
drug
also
immunomodulatori
properti
might
contribut
efficaci
vivo
standard
regimen
ofaerosol
ribavirin
consist
daili
dose
g
deliv
concentr
mgml
steril
water
hday
due
potenti
teratogen
drug
usual
administ
patient
within
scaveng
tent
prefer
neg
pressur
room
prevent
environment
contamin
administr
room
need
clean
minim
secondari
exposur
health
care
worker
visitor
women
childbear
potenti
care
visit
patient
receiv
aerosol
ribavirin
eas
administr
improv
complianc
drug
often
deliv
intermitt
dose
schedul
g
administ
h
everi
h
random
trial
subject
patient
receiv
intermitt
vs
continu
dose
lower
incid
progress
urti
lrti
report
durat
treatment
variabl
literatur
european
confer
infect
leukaemia
guidelin
recommend
durat
day
side
effect
aerosol
ribavirin
treatment
includ
cough
dyspnea
bronchospasm
rash
nausea
headach
conjunctiv
irrit
patient
also
experi
claustrophobia
deterior
pulmonari
function
ribavirin
also
administ
intraven
oral
major
side
effect
includ
hemolyt
anemia
leukopenia
hyperbilirubinemia
intraven
rsvspecif
immunoglobulin
rsvivig
palivizumab
pvz
licens
initi
prevent
seriou
complic
rsv
infect
highrisk
children
refer
section
immunoprophylaxi
also
employ
rsv
treatment
intraven
immunoglobulin
ivig
also
frequent
use
treatment
rsv
sever
viral
infect
transplant
recipi
efficaci
agent
prophylaxi
treatment
among
transplant
patient
evalu
random
control
trial
although
observ
studi
hsct
patient
rsv
lrti
multivari
analysi
find
effect
antibodybas
therapi
treatment
outcom
evalu
treatment
modal
rsv
respiratori
virus
limit
fact
publish
studi
small
observ
studi
lack
standard
definit
urti
lrti
use
differ
dosag
durat
therapi
subject
select
public
bia
among
dozen
report
treatment
rsv
hsct
patient
two
small
random
clinic
trial
one
studi
aerosol
ribavirin
discontinu
due
slow
accrual
enrol
patient
year
trial
enrol
patient
found
intermitt
dose
schedul
aerosol
ribavirin
treatment
rsv
urti
effect
continu
dose
schedul
prevent
progress
lrti
two
pool
analys
publish
studi
suggest
treatment
rsv
urti
lrti
aerosol
ribavirin
ivig
reduc
risk
progress
lrti
individu
urti
reduc
mortal
compar
treatment
aerosol
ribavirin
decreas
rate
progress
lrtiand
mortal
greatest
impact
observ
aerosol
ribavirin
given
combin
immunomodul
specif
compar
aerosol
ribavirin
treatment
alon
treatment
progress
lrti
decreas
mortal
rate
reduc
addit
immunomodul
pvz
ivig
andor
rsvivig
ribavirin
compar
treatment
decreas
progress
ltri
mortal
rate
pauciti
report
use
intraven
oral
ribavirin
combin
data
suggest
benefit
compar
treatment
import
recogn
neither
systemat
review
repres
formal
metaanalys
adjust
confound
thu
result
interpret
caution
trial
date
evalu
pvz
monotherapi
treatment
ofrsv
infect
hsct
recipi
show
benefit
prevent
progress
lrti
mortal
overal
analys
show
trend
toward
improv
outcom
regard
progress
lrti
mortal
among
hsct
recipi
treat
combin
aerosol
ribavirin
immunomodul
treat
aerosol
ribavirin
alon
intravenousor
ribavirin
given
treatment
howev
use
aerosol
ribavirin
cumbersom
costli
price
increas
per
day
addit
aerosol
form
ribavirin
avail
countri
intraven
form
commerci
avail
unit
state
experi
oral
ribavirin
hsct
limit
warrant
evalu
studi
suggest
may
safe
effect
altern
aerosol
ribavirin
treatment
rsv
retrospect
studi
hsct
recipi
rsv
infect
differ
rate
progress
lrti
mortal
among
patient
receiv
oral
compar
aerosol
ribavirin
optim
dose
oralribavirin
treatment
rsv
unclear
quit
variabl
literatur
commonli
describ
dose
strategi
includ
fix
dose
mg
two
three
time
day
load
dose
mgkg
follow
mgkgday
divid
three
dose
adjust
renal
failur
similar
hsct
popul
mainstay
treatment
paramyxovir
infect
sot
popul
aerosol
ribavirin
observ
studi
combin
aerosol
ribavirin
ivig
corticosteroid
found
safe
effect
preserv
lung
function
lung
transplant
recipi
rsv
piv
infect
studi
examin
role
oral
ribavirin
pelaez
et
al
report
treatment
five
lung
transplant
patient
rsv
infect
use
oral
ribavirin
combin
methylprednisolon
found
regimen
well
toler
effect
mean
forc
expiratori
volum
return
baselin
treatment
prospect
observ
studi
oral
ribavirin
treatment
patient
rsv
piv
hmpv
infect
associ
earlier
recoveri
graft
function
prevent
bo
compar
patient
support
care
includ
corticosteroid
one
studi
evalu
lung
transplant
patient
receiv
either
aerosol
oral
ribavirin
rsv
infect
signific
differ
outcom
note
two
group
variat
adjunct
therapi
eg
use
corticosteroid
ivig
andor
montelukast
might
alter
patient
clinic
respons
intraven
ribavirin
also
found
safe
costeffect
treatment
among
patient
rsv
lung
transplant
overal
studi
support
use
ribavirin
treat
rsv
infect
among
sot
recipi
although
import
recogn
evid
limit
small
uncontrol
studi
signific
variabl
among
studi
regard
dose
durat
treatment
well
use
immunomodul
agent
corticosteroid
ivig
pvz
adjunct
measur
recent
new
agent
presatovir
oral
bioavail
antivir
agent
inhibit
fusion
rsv
host
cell
membran
develop
treatment
rsv
infect
phase
ii
clinic
trial
studi
hsct
lung
transplant
recipi
complet
data
lung
transplant
recipi
publish
phase
random
control
trial
enrol
total
lung
transplant
patient
rsv
presatovir
appar
well
toler
use
result
improv
viral
clinic
outcom
four
distinct
serotyp
piv
name
virus
circul
throughout
year
commun
although
domin
serotyp
affect
transplant
popul
seem
highest
preval
spring
summer
season
piv
caus
spectrum
respiratori
tract
infect
similar
rsv
urti
result
fewer
hospit
lesser
extent
princip
caus
agent
croup
laryngotracheobronch
primarili
children
age
month
frequent
associ
pneumonia
bronchiol
neonat
immunocompromis
elderli
particular
risk
sever
diseas
isinfrequ
detect
andi
thought
caus
mostli
asymptomat
mild
infect
symptomat
piv
infect
affectsabout
hsct
recipi
andapproxim
lung
transplant
recipi
lrti
develop
pivinfect
hsct
patient
associ
mortal
rate
rang
two
larg
retrospect
studi
evalu
piv
infect
hsct
found
patient
present
urti
subsequ
progress
lrti
among
lrti
overal
mortal
day
independ
risk
factor
progress
lrti
includ
receipt
corticosteroid
time
urti
diagnosi
neutropenia
apach
ii
score
respiratori
coinfect
independ
predictor
death
includ
relaps
refractori
underli
cancer
apach
ii
score
highdos
corticosteroid
use
consid
patient
given
cumul
dose
prednisolon
mg
within
week
ofpiv
diagnosi
whether
steroid
still
import
adjust
lymphopenia
requir
studi
rsv
infect
alway
symptomat
asymptomat
shed
present
pivinfect
hsct
patient
surveil
studi
oflung
transplant
recipi
asymptomat
piv
infect
present
patient
piv
lrti
also
associ
significantli
increas
risk
sever
airflow
declin
hsct
compar
rsv
lung
transplant
patient
piv
associatedwith
acut
reject
bo
number
studi
report
treatment
ofpiv
ribavirin
see
section
treatment
rsv
limit
case
report
small
seri
hsct
aerosol
oralribavirin
employ
although
patient
receiv
intraven
ribavirin
respond
aerosol
oral
treatment
seri
includ
patient
lrti
treat
aerosol
ribavirin
without
ivig
nonrandom
fashion
therapi
appear
alter
mortal
pneumonia
decreas
durat
viral
shed
recent
retrospect
studi
evalu
hsct
recipi
piv
infect
fortyon
patient
lrti
treat
aerosol
ribavirin
without
ivig
mortal
group
similar
lrti
treat
ribavirin
overal
convinc
evid
ribavirin
effect
treatment
piv
upper
lower
tract
diseas
hct
recipi
effect
prophylaxi
treatment
piv
hsct
popul
desper
need
success
treatment
piv
lrti
report
heart
transplant
recipi
aerosol
ribavirin
intraven
ribavirin
plu
methylprednisolon
well
kidney
transplant
recipi
aerosol
ribavirin
ivig
although
none
studi
includ
control
novel
sialidas
fusion
protein
activ
multipl
strain
influenza
piv
use
piv
treatment
small
number
hsct
lung
transplant
recipi
drug
found
effect
case
well
toler
phase
ii
random
doubleblind
placebocontrol
studi
examin
effect
inimmunocompromis
host
lrti
piv
complet
result
publish
date
hmpv
first
describ
among
dutch
children
bronchiti
although
serolog
studi
indic
caus
human
infect
sinc
two
subgroup
hmpv
b
two
clade
four
subtyp
cocircul
singl
subtyp
tend
domin
year
hmpv
worldwid
distribut
circul
late
winter
earli
spring
temper
climat
late
spring
summer
tropic
region
hmpv
may
contribut
previous
virusneg
lrti
compar
rsv
infect
hmpv
tend
occur
slightli
older
children
caus
milder
symptom
sever
diseas
occur
among
small
children
elderli
immunosuppress
chronic
medic
condit
clinic
manifest
rang
mild
urti
sever
pneumonia
elderli
patient
much
like
experi
dyspnea
wheez
young
adult
hoars
common
complaint
compar
paramyxovirus
among
hospit
patient
recipi
hsct
wheez
promin
note
patient
patient
hematologicmalign
hsct
hmpv
respons
approxim
rvi
systemat
review
hmpv
infect
among
hsct
recipi
hematolog
malign
patient
found
despit
lack
direct
antivir
therapi
overal
mortal
rate
low
unless
patient
progress
lrti
approxim
onethird
patient
hmpv
urti
develop
lrti
lung
transplant
recipi
hmpv
isrespons
rvi
similar
morbid
compar
communityacquir
respiratori
virus
acut
hpmv
infect
associ
allograft
reject
studi
lung
transplant
patient
present
rvi
hmpv
rsv
equal
preval
similar
clinic
manifest
although
sever
bronchospasm
less
common
hmpv
signific
number
patient
either
hmpv
rsv
infect
develop
graft
dysfunct
respect
onset
progress
bo
occur
patient
rsv
month
none
hmpv
anoth
studi
lung
transplant
patient
also
show
hmpv
infect
increas
risk
acut
graft
rejectionwithout
associ
chronic
reject
bo
treatment
hmpv
larg
support
asther
current
antivir
therapi
licens
viru
ribavirin
activ
hmpv
vitro
anim
model
clinic
set
scatter
report
literatur
describ
hmpv
case
treat
success
use
aerosol
oral
intraven
ribavirin
given
without
ivig
howev
studi
includ
untreat
control
group
efficaci
regimen
determin
suggest
ribavirin
ivig
may
consid
treatment
option
patient
sever
diseas
approach
routin
use
sever
new
approach
treatment
hmpv
develop
includ
monoclon
antibodi
fusion
protein
synthet
peptid
withantivir
activ
efficaci
hmpv
demonstr
vitro
anim
model
studi
human
report
lrti
respiratori
virus
produc
spectrum
imag
find
common
highresolut
chest
comput
tomographi
hrct
scan
observ
includ
small
poorli
defin
centrilobular
nodul
treeinbud
opac
groundglass
opac
bronchial
wall
thicken
airspac
consolid
may
difficult
differenti
caus
pulmonari
consolid
consider
overlap
imag
appear
viral
bacteri
mycobacteri
fungal
respiratori
tract
infect
transplant
popul
find
treeinbud
opac
bronchial
wall
thicken
peribronchiolar
consolid
may
suggest
viral
etiolog
hrct
find
immunocompet
immunocompromis
patient
rel
similar
infect
copathogen
common
among
transplant
recipi
thu
complicatinginterpret
radiograph
find
correl
patient
immun
statu
recent
treatment
exposur
histori
well
epidemiolog
factor
essenti
help
narrow
list
possibl
etiolog
infecti
noninfecti
guid
diagnost
test
appropri
therapi
laboratori
diagnosi
respiratori
virus
isusu
made
analysi
respiratori
secret
sampl
obtain
nasal
wash
nasopharyng
throat
swab
bronchoalveolar
lavag
incub
tracheal
aspir
detect
viru
respiratori
sampl
perform
cell
cultur
antigen
test
pcr
viral
isol
cell
cultur
use
gold
standard
diagnosi
larg
replac
molecular
studi
revers
transcriptas
rt
routin
use
respiratori
viral
diagnosi
detect
rnavirus
respiratori
secret
higher
sensit
either
viral
cultur
antigen
detect
assay
particularli
immunocompromis
patient
compar
cultur
sensit
specif
rtpcr
techniqu
reach
respect
pcrbase
test
respiratori
viral
detect
often
design
part
multiplex
pcr
assay
allow
detect
multipl
respiratori
pathogen
simultan
rapid
pointofcaretest
develop
well
pvz
rsvspecif
human
monoclon
antibodi
direct
f
glycoprotein
rsv
fda
approv
immunoprophylaxi
rsv
highrisk
children
data
use
immunocompromis
adult
patient
limit
one
uncontrol
studi
literatur
report
use
pvz
immunoprophylaxi
rsv
outbreak
adult
hsct
unit
rsvivig
prophylaxi
also
studi
highrisk
adult
hsct
recipi
increas
antibodi
titer
rsv
demonstr
studi
underpow
evalu
efficaci
sever
monoclon
antibodi
rsv
develop
despit
major
clinic
import
ofparamyxovirus
current
vaccin
approv
virus
human
use
variou
strategi
vaccin
develop
test
anim
model
includ
liveattenu
viru
vaccin
includ
chimer
recombin
varieti
inactiv
viru
vaccin
subunit
vaccin
number
current
phase
clinic
trial
retrospect
studi
hsct
patient
pretranspl
rsv
urti
patient
transplant
delay
condit
abort
overal
rsv
pneumonia
occur
patient
hsct
delay
compar
two
three
patient
delay
studi
suggest
hsct
candid
pretranspl
rsv
urti
delay
hsct
might
reduc
risk
develop
rsv
pneumonia
thu
strategi
delay
transplant
prevent
progress
viral
urti
lrti
recommend
unless
preclud
progress
underli
malign
limit
data
respiratori
virus
although
propos
guidanc
avail
tabl
influenza
signific
caus
morbid
mortal
transplant
patient
recipi
solid
organ
transplant
urti
lrti
may
due
influenza
infect
annual
pandem
mortal
rate
rang
case
seri
although
one
studi
report
mortal
rate
among
lung
transplant
recipi
organ
transplant
lung
transplant
recipi
appear
highest
risk
one
studi
incid
influenza
time
higher
recipi
lung
transplant
compar
recipi
solid
organ
kidney
liver
incid
influenza
among
hsct
rang
patient
may
develop
lrti
death
rate
associ
influenza
hsct
recipi
higher
sot
among
patient
lrti
mortal
rate
rang
case
fatal
rate
pandem
rang
main
risk
factor
diseas
progress
lrti
lymphopenia
allogen
hsct
infect
earli
posttranspl
period
presenc
graftversushost
diseas
myeloabl
preparatori
regimen
delay
initi
antivir
therapi
risk
factor
interest
concomit
corticosteroid
use
associ
increas
risk
progress
lrti
need
mechan
ventil
infect
associ
death
howev
patient
given
system
higher
dose
mgkg
corticosteroid
may
predispos
prolong
viral
shed
potenti
role
corticosteroid
influenc
risk
progress
lrti
mortal
influenza
respiratori
viral
infect
summar
tabl
clinic
manifest
influenza
similar
immunocompet
patient
multicent
cohort
studi
organ
transplant
patient
pandem
common
present
symptom
cough
fever
myalgia
gastrointestin
symptom
rhinorrhea
sore
throat
multicent
cohort
studi
hsct
recipi
pandem
common
present
symptom
cough
fever
rhinorrhea
myalgia
sore
throat
howev
atyp
present
may
occur
signific
immunosuppress
may
includ
fever
present
symptom
afebril
patient
rhinorrhea
alon
specul
corticosteroid
use
blunt
cytokin
respons
associ
acut
influenza
infect
patient
may
contribut
reduct
absenc
ofsystem
symptom
select
patient
primari
complic
influenza
infect
transplant
patient
progress
urti
lrti
lead
acut
lung
injuri
death
morbid
mortal
appear
greatest
among
hsct
lung
transplant
recipi
diffus
peribronchi
groundglass
opac
typic
radiograph
appear
patient
lrti
centrilobular
nodul
frank
lower
lobe
consolid
also
observ
coinfect
viral
bacteri
fungal
pathogen
may
occur
report
patient
multicent
studi
sot
recipi
pandem
influenza
compar
viral
copathogen
patient
bacteri
fungal
coinfect
wors
outcom
although
uncommon
influenza
also
caus
varieti
extrapulmonari
complic
includ
myocard
myositi
encephalopathi
renal
failur
sever
diarrhea
pneumomediastinum
virusassoci
hemophagocyt
syndrom
report
sever
complic
pandem
lead
multiorgan
failur
discuss
previous
sever
studi
suggest
associ
rvi
includ
influenza
allograft
rejectionbo
case
lung
transplant
other
prospect
studi
need
better
character
impact
infect
longterm
sequela
healthi
adult
season
influenza
virusshed
rang
day
may
extend
beyond
week
hospit
patient
even
longer
transplant
recipi
median
durat
viral
shed
among
allogen
hsct
recipi
day
compar
week
among
recipi
autolog
transplant
prolong
viral
shed
beyond
week
case
month
describ
hsct
recipi
risk
factor
prolong
viral
shed
includ
use
corticosteroid
dosag
mgkg
per
day
use
bone
marrow
cord
blood
versu
peripher
blood
stem
cell
sever
method
availablefor
detect
influenza
includ
rapid
antigen
direct
immunofluoresc
antibodi
dfa
viral
cultur
pcr
respiratori
virus
molecular
test
larg
replac
test
modal
studi
evalu
test
characterist
four
differ
diagnost
assay
pandem
pcr
found
greatest
sensit
specif
given
improv
sensit
specif
method
pcr
nucleic
acidbas
detect
assay
prefer
diagnosi
influenza
infect
suscept
patient
popul
multiplex
pcr
ad
advantag
identifi
caus
respiratori
viral
infect
well
current
two
major
class
ofantivir
agent
activ
influenza
adamantan
block
viral
protein
ion
channel
therebi
prevent
fusion
viru
host
cell
membran
neuraminidas
inhibitor
prevent
releas
progeni
viru
infect
cell
adamantan
amantadin
rimantadin
activ
influenza
neuraminidas
inhibitor
oseltamivir
zanamivir
activ
influenza
b
virus
although
reduc
effect
oseltamivir
occasion
report
influenza
b
viru
develop
resist
adamantanesamong
influenza
viru
substanti
limit
util
clinic
practic
although
season
remain
suscept
adamantan
resist
emerg
among
season
widespread
among
pandem
virus
oseltamivir
resist
first
emerg
among
season
virus
describ
pandem
oseltamivir
resist
primarili
confer
mutat
result
crossresist
zanamivir
pcr
test
avail
detect
mutat
n
mutat
detect
strain
pandem
collect
asia
found
confer
low
moder
oseltamivir
zanamivir
resist
otherwis
littl
zanamivir
resistancereport
date
thu
recommend
treatment
oseltamivirresist
influenza
infect
resist
pattern
evolv
time
clinician
becom
familiar
local
pattern
influenza
circul
commun
throughout
influenza
season
refer
center
diseas
control
prevent
cdc
influenzawebsit
http
wwwcdcgovflu
updat
inform
regard
antivir
resist
recommend
regard
antivir
use
addit
antivir
resist
appear
occur
commonli
among
sever
immunocompromis
patient
like
due
prolong
viral
shed
pandem
major
patient
oseltamivirresist
viru
report
cdc
hsct
recipi
patient
hematolog
malign
receiv
chemo
immunosuppress
therapi
randomizedclin
trial
antivir
therapi
influenza
transplant
patient
random
trial
includ
healthi
adult
outpati
treat
within
h
symptom
onset
aggreg
demonstr
reduct
durat
symptom
day
time
return
normal
activ
although
studi
need
regard
role
antivir
therapi
h
symptom
onset
idsa
guidelin
manag
season
influenza
suggest
antivir
therapi
initi
h
symptom
onset
may
benefici
hospit
patient
base
prospect
cohort
studi
observ
studi
suggest
earli
antivir
therapi
hsct
recipi
influenza
urti
effect
prevent
progress
lrti
among
sot
recipi
multicent
studi
found
earli
antivir
therapi
associ
lower
incid
hospit
likelihood
icu
admiss
compar
delay
h
symptom
onset
therapi
although
antivir
therapi
may
greatest
valu
initi
earli
felt
symptomat
transplant
patient
may
benefit
even
beyond
h
evid
viral
replic
gener
treatment
symptomat
transplant
patient
recommend
regardless
durat
symptom
optim
dose
durat
antivir
therapi
transplant
patient
establish
oseltamivir
studi
dose
mg
mg
twice
daili
immunocompet
patient
season
influenza
significantadvantag
higher
dose
although
slightli
higher
rate
advers
effect
observ
howev
due
concern
higher
viral
load
prolong
viral
shed
uncertain
drug
absorpt
particularli
patient
undergo
chemotherapi
gastrointestin
graftversushost
diseas
expert
suggest
use
higher
dose
transplant
patient
particularli
absorpt
uncertain
patient
sever
lrti
orwho
critic
ill
base
clinic
studi
healthi
adult
recommend
durat
treatment
influenza
immunocompet
patient
day
howev
transplant
patient
may
need
longer
durat
therapi
due
prolong
viral
shed
expert
recommend
treat
sot
recipi
viral
replic
ceas
author
recommend
check
pcr
week
treat
neg
other
suggest
cours
hsct
recipi
extend
treatment
patient
pneumonia
ongo
symptom
viral
shed
resist
test
consid
patient
persist
viral
shed
progress
despit
antivir
therapi
literatur
transplant
recipientsha
focus
oseltamivir
inhal
zanamivir
appear
reason
altern
iv
zanamivir
current
avail
compassion
use
limit
publish
experi
among
transplant
recipi
use
benefit
among
patient
oseltamivirresist
influenza
sever
diseas
peramivir
parenter
neuraminidaseinhibitor
fda
approv
treatment
uncompl
influenza
infect
adult
ill
day
limit
data
regard
use
peramivir
transplant
recipi
note
mutat
confer
oseltamivir
resist
also
confer
crossresist
peramivir
current
data
indic
clear
clinic
benefit
combin
antivir
therapi
singl
drug
therapi
random
doubleblind
multicent
phase
trial
found
combin
antivir
therapi
oseltamivir
amantadin
ribavirin
reduc
day
viral
shed
compar
oseltamivir
monotherapi
differ
clinic
outcom
includ
resolut
symptom
fever
time
recoveri
ill
tabl
summar
antivir
option
fortreat
influenza
annual
influenza
vaccin
keycompon
infect
prevent
among
hsct
sot
recipi
sever
type
influenza
vaccin
standarddos
inactiv
influenza
vaccin
iiv
avail
either
trival
quadrival
inject
highdos
iiv
avail
trival
inject
live
attenu
influenza
vaccin
laiv
intraderm
iiv
recombin
eggfre
iiv
vaccin
modifi
annual
base
anticip
circul
strain
upcom
influenza
season
laiv
contraind
immunocompromis
patient
use
transplant
recipi
intraderm
iiv
hasnot
evalu
transplant
recipi
hsct
recipi
influenza
vaccin
recommend
month
posttranspl
begin
month
follow
transplant
commun
influenza
outbreak
vaccin
administ
earlier
month
hsct
second
dose
consid
time
vaccin
administr
appear
predict
respons
one
studi
demonstr
influenza
immun
least
month
afterhct
effect
prevent
influenza
highdos
trival
iiv
fda
approv
individu
year
age
found
multicent
random
clinic
trial
induc
higher
antibodi
respons
improv
protect
influenza
compar
standard
dose
iiv
phase
trial
hsct
recipi
random
receiv
highdos
trival
iiv
evid
greater
immunogen
compar
receiv
standarddos
trival
iiv
higher
frequenc
inject
site
reaction
mild
ongo
studi
evalu
role
highdos
iiv
hsct
sot
recipi
influenza
vaccin
isrecommend
month
transplant
immunogen
influenza
vaccin
follow
sot
variabl
depend
type
transplant
time
transplant
immunosuppress
regimen
among
sot
recipi
overal
respons
base
seroprotect
seroconvers
rang
greater
respons
observ
sever
year
kidney
transplant
lower
respons
seen
lung
transplant
although
theoret
concern
influenza
immun
may
associ
earli
allograft
reject
allosensit
patient
transplant
observ
clinic
trial
random
doubleblind
trial
sot
recipi
highdos
influenza
vaccin
demonstr
significantli
better
immunogen
standarddos
vaccin
increas
risk
reject
report
although
studywa
power
address
outcom
immun
health
care
worker
household
contact
transplant
recipi
critic
compon
influenza
prevent
strongli
recommend
publish
guidelin
systemat
review
suggest
vaccin
healthcar
worker
reduc
influenzalik
ill
allcaus
mortal
elderli
due
theoret
risk
oftransmiss
laiv
cdc
recommend
iiv
use
household
member
health
care
worker
close
contact
sever
immunosuppress
patient
recipi
hematopoiet
stem
cell
allograft
transplant
period
patient
requir
care
protect
environ
person
receiv
laiv
avoid
provid
care
contact
patient
day
vaccin
although
influenza
vaccin
primari
tool
influenza
prevent
antivir
chemoprophylaxi
may
consid
prevent
strategi
select
situat
idsa
guidelin
manag
season
influenza
recommendsconsider
antivir
chemoprophylaxi
highrisk
patient
week
vaccin
adequ
immun
respons
develop
influenza
circul
commun
also
consid
among
transplant
recipi
follow
exposur
within
previou
h
individu
influenza
particularli
among
vaccin
contraind
unavail
expect
low
effect
patient
sever
immun
suppress
choic
chemoprophylact
agent
depend
suscept
pattern
circul
influenza
strain
hrv
hcov
also
common
caus
rvi
human
classifi
picornaviridia
famili
genu
enteroviru
coronaviria
famili
respect
approxim
serotyp
hrv
identifi
comparison
two
known
hcov
year
new
hcov
identifi
caus
agent
outbreak
sever
acut
respiratori
syndrom
sar
name
sarscov
subsequ
two
new
hcov
discov
respect
latter
part
anoth
novel
cov
identifi
caus
sever
respiratori
ill
two
adult
middl
east
term
middl
east
respiratori
syndrom
coronaviru
merscov
similar
sarscov
viru
also
caus
sever
lifethreaten
diseas
abil
emerg
hcov
caus
major
outbreak
potenti
threat
global
public
health
economi
immunocompet
host
hrv
hcov
usual
caus
urti
hcov
also
caus
croup
wheez
well
pneumonia
sever
signific
mortal
case
sar
signific
hrv
hcov
transplant
popul
well
establish
accord
prospect
studi
hsct
recipi
infect
virus
appear
common
first
day
allogen
transplant
day
cumul
incid
estim
hrv
hcov
hrv
infect
associ
urti
sign
symptom
hcov
infect
asymptomat
half
infect
patient
prolong
viral
shed
week
shed
viru
month
patient
develop
lrti
studi
fatal
pneumonia
associ
hrv
hcov
report
among
hsct
recipi
recent
studi
suggest
hrv
hcov
lrti
viral
detect
bal
associ
mortal
rate
similar
seen
rsv
piv
influenza
virus
sot
hrv
hcov
frequent
isol
among
lung
transplant
patient
major
patient
asymptomat
accord
prospect
surveil
studi
discuss
previous
rvi
increas
risk
develop
acut
reject
andor
bo
even
asymptomat
infect
whether
hrv
hcov
infect
confer
level
risk
compar
paramyxovirus
influenza
delin
studi
current
specif
agent
licens
treatment
hrv
hcov
antivir
therapi
enterovirus
intens
research
respiratori
viral
infect
common
associ
signific
morbid
mortal
among
patient
undergo
hematopoiet
stem
cell
solid
organ
transplant
optim
manag
infect
limit
insuffici
random
treatment
data
well
limit
new
novel
antivir
drug
investig
potenti
clinic
use
larg
prefer
multicent
prospect
random
trial
essenti
assess
prefer
therapi
lifethreaten
infect
rsv
defin
role
combin
antivir
influenza
viru
infect
determin
use
adjunct
immunomodulatori
therapi
andor
corticosteroid
manag
infect
among
highli
suscept
transplant
popul
evalu
novel
longlast
potent
monoclon
antibodi
prevent
may
warrant
